Major rise in the geriatric population throughout the globe will lead the Global Hypertension Drug Market to the higher level.

NEW YORK, NY, UNITED STATES, March 17, 2020 /EINPresswire.com/ -- Goldstein Research recently published a report titled, “Global Hypertension Drugs Market Outlook 2024” which indicates hypertension drugs market size to reach USD 33.1 billion by 2024 growing at 1.12% CAGR through 2024. The rising geriatric population across the globe is driving the growth of the market. The US has recently experienced growth in sales of hypertension drugs due to the spread of new disease-modifying therapies. As per WHO statistics, nearly 22% of adults aged over 18yrs have increased blood pressure and nearly 52% American adults suffering from high blood pressure have their condition under control. Further, based on segmentation, systematic hypertension drugs segment accounted for the highest market share of 85.0% in 2016.

Request Sample Report @ http://bit.ly/38UqwSI

Hypertension: The Silent Killer Spreading Across Africa

 An estimated one billion people live with what is more commonly known as high blood pressure. Of these, more than nine million die from the condition each year.

 As anti-retroviral treatment is rolled out to everyone living with HIV, and general improvements in health care take place, life expectancy is increasing. The incidence of hypertension is therefore likely to rise. It’s projected that 75% of older people will be hypertensive in low and middle income countries by 2024

 In South Africa, for example, up to 50% of the people between the ages of 40 and 60 suffered from high blood pressure. In rural Burkino Faso though, there was only a 15% prevalence.

 Hypertension rates were low in West Africa, higher in East Africa. Prevalence ranged from 15% in West Africa to 25% in East Africa, and between 42% and 54% in South Africa.

 South Africa on the other hand has the highest prevalence of hypertension on the continent. Diets are rich in refined and fast foods, lifestyles are sedentary, and obesity is a norm. It also has the largest number of people whose blood pressure is still not controlled despite them being on treatment.

Drivers & Restraints to Market Growth
Increase in R&D productivity, Healthy appetite for M&A seen across the board and Prescription drugs sales are set to advance market growth at global level. On the other hand Struggling Side Effects, Availability of major players and Patent Expiration issues are expected to impede growth in near future. However, development in emerging economies is expected to create multiple opportunities in the industry.

Report is available @ http://bit.ly/2QgfqkE

“Global Hypertension drugs Market Outlook 2024” by Goldstein Research contains detailed overview of the global hypertension drugs market in terms of market segmentation by analysis basis, therapy type and geography.
The Report highlights the competitive outlook of major global players that includes the business strategies, product portfolio, revenue distribution, financial analysis, R&D activities, and investments. The in-depth analysis of hypertension drugs market report will help the clients to assess their business strategies as per the competitive environment in the market space.

Major players of the global hypertension drugs market discussed in the report are:
• Lupin Limited
• Novartis AG
• Sun Pharmaceuticals LLC
• Daiichi – Sankyo
• Pfizer Inc.
• Sanofi S.A
• AstraZeneca Plc.
• Johnson & Johnson Ltd.
• BoehringerIngelheim
• Merck & Co
• Roche
• Abbott, GlaxoSmithKline plc.
• AstraZeneca
• Bayer AG
• Gilead Actelion
• Symplmed Pharmaceuticals
• Takeda Pharmaceuticals
• United Therapeutics
• Valeant Pharmaceuticals
• XOMA
• Yuhan
• Ono Pharmaceutical
• Northern Therapeutics
• Mast Therapeutics
• Eiger Bio Pharmaceuticals

Further, Global Hypertension Drugs Market Analysis Report encompasses the major trends & growth opportunities, market dynamics and other growth factors. The Hypertension drugs Market outlook also comprises of key challenges for the market players, risk analysis, SWOT Analysis, USP Analysis, BPS analysis, and Market Attractiveness. The report also includes the expert analysis which provides a complete overview of the market post analysis of the economic, political, environmental & social factors of each region and country.

About Goldstein Research
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear-cut forecasts. Our market research reports provide in-depth analysis of global and regional variations along with competitors’ overview.

Our analysts working on healthcare market research reports to help various tech-giants, tech start-ups and entry players to assess the current and upcoming business scenario. We believe in the vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.
Contact for more Info:
Steve Blade
(Global Sales Head)
USA: + 1-646-568-7747
Canada: 1-437-886-1181
UK: +44-203-318-6627
sales@goldsteinresearch.com
www.goldsteinresearch.com

Steve blade
Goldstein Researchh
+1 646-568-7747
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.